Author

Anna Hanxi He

Observed names: Anna H He, Anna H. He, Anna He, Anna He (18643591), He, A, He, Anna, He, Anna H

Institutions: Karolinska University Hospital, The Alfred Hospital, Karolinska Institutet, National Hospital for Neurology and Neurosurgery, Alfred Health, UCL Queen Square Institute of Neurology, University College London, Monash University

Observed institutions: The Royal Melbourne Hospital, Karolinska University Hospital, Max Planck Society, The University of Melbourne, The Alfred Hospital, Karolinska Institutet, National Institute for Health and Care Research, Amsterdam Neuroscience, Max Planck Institute for Human Cognitive and Brain Sciences, UCL Biomedical Research Centre, National Hospital for Neurology and Neurosurgery, Alfred Health, UCL Queen Square Institute of Neurology, University College London, Monash University

ORCID: 0000-0002-6924-8798

Observed ORCID: 0000-0002-6924-8798

OpenAlex ID: A5046409934

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

2020 · Anna He, Bernd Merkel, et al. · The Lancet Neurology · 466

Predicting free choices for abstract intentions

2013 · Chun Siong Soon, Anna Hanxi He, et al. · Proceedings of the National Academy of Sciences · 275

Tracking the Unconscious Generation of Free Decisions Using UItra-High Field fMRI

2011 · Stefan Bode, Anna Hanxi He, et al. · PLoS ONE · 150

PDF

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

2015 · Anna He, Tim Spelman, et al. · JAMA Neurology · 110

PDF

Every 15-Min Delay in Recanalization by Intra-Arterial Therapy in Acute Ischemic Stroke Increases Risk of Poor Outcome

2015 · Anna H. He, Leonid Churilov, et al. · International Journal of Stroke · 42

PDF

Hyperdense middle cerebral artery sign is associated with increased risk of hemorrhagic transformation after intravenous thrombolysis for patients with acute ischaemic stroke

2013 · Ming Zou, Leonid Churilov, et al. · Journal of Clinical Neuroscience · 40

Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning

2024 · Giuseppe Pontillo, Ferran Prados, et al. · Neurology · 22

PDF

Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study

2022 · Anna He, Tim Spelman, et al. · Journal of Neurology Neurosurgery & Psychiatry · 19

Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context

2023 · Anna He, Ali Manouchehrinia, et al. · JAMA Network Open · 16

PDF

The temporal dynamics and clinical relevance of choroid plexus measures in multiple sclerosis

2025 · Ermelinda De Meo, Sarmad Al-Araji, et al. · Brain Communications · 12

PDF

Completeness and generalizability of the Swedish MS register

2025 · Peter Alping, Thomas Frisell, et al. · European Journal of Epidemiology · 11

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

2021 · Kyla A. McKay, Fredrik Piehl, et al. · JAMA Network Open · 11

PDF

Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis

2024 · Ronja Christensen, Amy Jolly, et al. · Multiple Sclerosis Journal · 9

Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden

2022 · Fitsum Sebsibe Teni, Alejandra Machado, et al. · Multiple Sclerosis and Related Disorders · 5

PDF

Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile

2025 · Ronja Christensen, Alessandro Cruciani, et al. · BMJ Open · 3

PDF

Optical coherence tomography angiography reveals insights into complementary vascular and neurodegenerative mechanisms in multiple sclerosis

2026 · Charmaine Hiu-Ying Yam, Danuta M Sampson, et al. · Brain Communications · 2

Socioeconomic status and quality of multiple sclerosis care in Sweden

2024 · Anna He, Ali Manouchehrinia, et al. · Multiple Sclerosis and Related Disorders · 2

PDF

Disentangling neurodegeneration from ageing in multiple sclerosis: the brain-predicted disease duration gap

2024 · Giuseppe Pontillo, Ferran Prados, et al. · medRxiv · 2

PDF

Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosis

2025 · Marianne J Shawe-Taylor, David Greenwood, et al. · BMJ Neurology Open · 1

PDF

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis

2023 · Anna H He, Ali Manouchehrinia, et al. · Multiple Sclerosis Journal · 1

PDF

Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions

2026 · Pakeeran Siriratnam, Mineesh Datta, et al. · Autoimmunity Reviews

Data-Driven Fatigue Trajectories in Multiple Sclerosis and Their Predictors

2026 · Alessandro Cruciani, Emanuele Olivieri, et al. · Neurology Neuroimmunology & Neuroinflammation

Changes in Multiple Sclerosis Clinical Care and Outcomes During the COVID‐19 Era: A Population‐Wide Study

2026 · Giuseppina Affinito, Anna He, et al. · Acta Neurologica Scandinavica

PDF

Predicting Treatment Responses in Multiple Sclerosis: A Model Development and Geographical Validation Study

2026 · Sarmad Al-Araji, Ashwani Jha, et al. · SSRN Electronic Journal

Predicting treatment responses in multiple sclerosis: a model development and geographical validation study

2026 · Sarmad Al-Araji, Ashwani Jha, et al. · SSRN Electronic Journal

Works count: 37

Citation count: 1,199

H-index: 11

I10-index: 12